book chapter · Advances in computational intelligence and robotics book series
Combining artificial intelligence with advanced cellular technologies, including genome, epigenome, and mitochondrial therapies, enhances precision medicine and therapeutic efficacy. However, these technical advances disrupt established bioethical and regulatory frameworks. Major ethical dilemmas include the blurring boundary between somatic and germline alterations, population-specific algorithmic biases, and heritable modifications linked to mitochondrial replacement therapies. Significant legal challenges also emerge, notably clinical liability for opaque predictions generated by artificial intelligence, friction over intellectual property, and regulatory gaps concerning reversible epigenetic modifications. On a social level, these interventions risk expanding the genomic divide, impacting disability rights, and heightening public anxiety. Navigating these converging challenges requires adaptive, global governance structures to protect human agency.
Rapid advances in artificial intelligence and cellular editing promise improved therapies, yet they also pose profound risks to equity and safety. Without updated oversight, these tools could entrench systemic biases and outpace existing laws. Addressing these governance challenges is essential for ensuring that future medical treatments remain legally accountable, socially equitable, and aligned with human agency.
The work highlights significant regulatory and legal hurdles facing commercial ventures in artificial intelligence and cellular engineering. Developers and healthcare providers face liability risks from opaque algorithms, intellectual property conflicts, and ambiguous oversight for epigenetic therapies. Because the abstract focuses on governance analysis rather than technical deployment, these technologies appear to face complex, early-stage regulatory compliance barriers before widespread commercial translation can occur safely.
AI-generated from the published abstract. Always read the original work before citing.
This chapter per the authors explores the integration of Artificial Intelligence (AI) with advanced cellular technologies, including genome, epigenome, and mitochondrial therapies, and examines the resulting ethical, legal, and social implications (ELSI). This chapter per the authors argues that while AI optimization enhances precision medicine and therapeutic efficacy, it simultaneously disrupts traditional bioethical and regulatory frameworks. The text details critical ethical concerns, such as the blurring of the somatic-germline divide, population-specific algorithmic biases, and heritable modifications in mitochondrial replacement therapies. Legally, this chapter per the authors highlights challenges regarding clinical liability for opaque AI-generated predictions, intellectual property friction, and regulatory gaps in reversible epigenetic modifications. Socially, this chapter per the authors addresses the emerging “genomic divide,” disability rights, and public anxieties.Ultimately, this chapter per the authors advocates for adaptive, global governance to protect human agency.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4018/979-8-2600-0161-5.ch015
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
